Assessment of the clinical effectiveness and safety of immune checkpoint inhibitors for glioblastoma: A systematic review

Assessment of the clinical effectiveness and safety of immune checkpoint inhibitors for glioblastoma: A systematic review

Glioblastoma (GBM) is a malignant primary brain tumor which is commonly found in humans. Conventional therapeutic approaches for GBM offer only a short median overall survival (MOS), thereby accentuating its poor clinical outcome. Despite the promising potential shown by use of immune checkpoint inh...

Full description

Bibliographic Details
Main Authors:	Nicholas Calvin, Fridoline Sharon Octo
Format:	Article
Language:	English
Published:	Amaltea Medical Publishing House 2023-12-01
Series:	Romanian Journal of Neurology
Subjects:	glioblastoma immune checkpoint inhibitors overall survival progression free survival safety
Online Access:	https://rjn.com.ro/articles/2023.4/RJN_2023_4_Art-02.pdf

Similar Items

Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors
by: Shuai Jiang, et al.
Published: (2022-09-01)

Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan
by: Hisanaga K, et al.
Published: (2021-02-01)

Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan [Corrigendum]
by: Hisanaga K, et al.
Published: (2021-07-01)

Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients
by: Xuan-Zhang Huang, et al.
Published: (2019-12-01)

Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Donggun Lee, et al.
Published: (2021-11-01)

Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study
by: Rong Liu, et al.
Published: (2021-06-01)

Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors
by: Hye Ryeon Kim, et al.
Published: (2022-07-01)

Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Yue An, et al.
Published: (2020-06-01)

Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
by: Qi Cai, et al.
Published: (2022-12-01)

Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study
by: Liyun Zheng, et al.
Published: (2021-01-01)

Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients
by: Luying Wan, et al.
Published: (2023-01-01)

Correlation between patients’ age and cancer immunotherapy efficacy
by: Qiong Wu, et al.
Published: (2019-04-01)

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
by: Yinghong Wang, et al.
Published: (2018-05-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients
by: Damir Vucinic, et al.
Published: (2024-03-01)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
by: Yongfeng Wu, et al.
Published: (2019-11-01)

Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer
by: Bao-Dong Qin, et al.
Published: (2021-01-01)

Treatment Strategies for Glioblastoma in the Elderly: What Should We Focus on Compared to Younger Patients
by: Hanah Hadice Gull, et al.
Published: (2024-03-01)

Predicting Survival in Glioblastoma Patients Using Diffusion MR Imaging Metrics—A Systematic Review
by: Valentina Brancato, et al.
Published: (2020-10-01)

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
by: Ehsan Alimohammadi, et al.
Published: (2020-02-01)

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Jong Yeob Kim, et al.
Published: (2019-11-01)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
by: Francesco Marchi, et al.
Published: (2020-01-01)

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
by: Hong-Fei Zhu, et al.
Published: (2023-06-01)

Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2020-12-01)

Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity
by: Andrea Cardia, et al.
Published: (2023-03-01)

Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma
by: Stephanie Sanders, et al.
Published: (2020-04-01)

Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors in Treatment of Glioblastoma
by: LI Yingying, et al.
Published: (2022-05-01)

PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors
by: Sisi Zhang, et al.
Published: (2023-11-01)

Efficacy and Safety Evaluation of Sintilimab for Cancer Treatment: A Systematic Review and Meta-analysis of Randomized Controlled Trials
by: Ziqi Ye, et al.
Published: (2022-04-01)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
by: David J. Pinato, et al.
Published: (2019-11-01)

Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
by: Guang‐Li Zhu, et al.
Published: (2021-12-01)

Development and Assessment of Nomogram Based on AFP Response for Patients with Unresectable Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
by: Yi Zhang, et al.
Published: (2023-10-01)

Risk factors for deep venous thrombosis in patients with advanced lung cancer after treatment of immune checkpoint inhibitors
by: CHEN Wen, et al.
Published: (2022-11-01)

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
by: Wenchao Yang, et al.
Published: (2022-08-01)

Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis
by: Laurentiu Simion, et al.
Published: (2023-03-01)

Immune-checkpoint inhibitors for glioblastoma: what have we learned?
by: Antonio Omuro
Published: (2022-08-01)

Assessment of Pre-operative Measurements of Tumor Size by MRI Methods as Survival Predictors in Wild Type IDH Glioblastoma
by: Alexis Palpan Flores, et al.
Published: (2020-09-01)

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study
by: Guosheng Yuan, et al.
Published: (2024-03-01)

Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials
by: Ibrahim Elmakaty, et al.
Published: (2023-05-01)

The Prognostic Role of Volumetric MRI Evaluation in the Surgical Treatment of Glioblastoma
by: Denis Aiudi, et al.
Published: (2024-02-01)

Revalidation of the ATTRACTION-4 study in a real-world setting: a multicenter, retrospective propensity score matching study in China
by: Yuhong Dai, et al.
Published: (2023-09-01)